
MC-Val-Cit-PAB-Exatecan

Cat. No.: HY-145929 CAS No.: 2504068-28-2 Molecular Formula: C₅₃H₆₀FN₉O₁₂ Molecular Weight: 1034.1

Drug-Linker Conjugates for ADC Target:

Pathway: Antibody-drug Conjugate/ADC Related Storage: 4°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (48.35 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	0.9670 mL	4.8351 mL	9.6702 mL
	5 mM	0.1934 mL	0.9670 mL	1.9340 mL
	10 mM	0.0967 mL	0.4835 mL	0.9670 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (1.21 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 1.25 mg/mL (1.21 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description	MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. MC-Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker.
IC ₅₀ & Target	Camptothecins
In Vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

1]. Anish Thomas, et al. Antibody-dru	ug conjugates for cancer thera	py. Lancet Oncol. 2016 Jun;17	(6):e254-e262.		
			l applications. For research		
Tel:		ax: 609-228-5909 ark Dr, Suite Q, Monmouth	E-mail: tech@MedChemExp Junction, NJ 08852, USA	ress.com	
		, ,	, ,		

Page 2 of 2 www.MedChemExpress.com